Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mirum Pharmaceuticals, Inc.

https://mirumpharma.com

Latest From Mirum Pharmaceuticals, Inc.

Dengue Vaccine Qdenga & Nine Drugs Win EMA Thumbs Up

The European Medicines Agency has delivered its verdict on marketing applications for a raft of new medicines.

Europe International

Albireo Ready To Seek Second Bylvay Indication In Alagille Syndrome

With Bylvay approved last year for progressive familial intrahepatic cholestasis, Albireo looks to add an estimated 25,000 addressable patients to IBAT inhibitor’s label with strong Phase III data in ALGS.

Business Strategies Clinical Trials

EU Moment of Truth For Abaloparatide & Advanced Therapy Tab-Cel

Radius’s abaloparatide, which was previously rejected by the European Medicine Agency, is among the latest products that are this week being considered for EU-wide marketing approval by the agency.

Europe Approvals

Mirum Awaits EMA Verdict On ‘Reprioritized’ Livmarli Filing

Mirum could soon find out if its decision to reprioritize its EU filings for its rare liver disease drug has paid off.

Europe Drug Review
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
UsernamePublicRestriction

Register